U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C23H25N5O5
Molecular Weight 451.476
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOXAZOSIN

SMILES

COc1cc2c(cc1OC)nc([nH]c2=N)N3CCN(CC3)C(=O)C4COc5ccccc5O4

InChI

InChIKey=RUZYUOTYCVRMRZ-UHFFFAOYSA-N
InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)

HIDE SMILES / InChI
Doxazosin mesylate is a quinazoline compound sold by Pfizer under the brand name CARDURA. CARDURA is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with CARDURA monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in 66–71% of patients. CARDURA is also indicated for the treatment of hypertension. CARDURA may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angiotensin-converting enzyme inhibitors. Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.

Originator

Curator's Comment:: # Pfizer

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CARDURA

Approved Use

INDICATIONS AND USAGE A. Benign Prostatic Hyperplasia (BPH). CARDURA is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with CARDURA monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in 66–71% of patients. Sustained improvements with CARDURA were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. B. Hypertension. CARDURA is also indicated for the treatment of hypertension. CARDURA may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angiotensin-converting enzyme inhibitors.

Launch Date

6.5750401E11
Primary
CARDURA

Approved Use

INDICATIONS AND USAGE A. Benign Prostatic Hyperplasia (BPH). CARDURA is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). CARDURA may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with CARDURA monotherapy. CARDURA provides rapid improvement in symptoms and urinary flow rate in 66–71% of patients. Sustained improvements with CARDURA were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. B. Hypertension. CARDURA is also indicated for the treatment of hypertension. CARDURA may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angiotensin-converting enzyme inhibitors.

Launch Date

6.5750401E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.7 ng/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
13.6 ng/mL
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
14.3 ng/mL
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
151.7 ng/mL
16 mg 1 times / day steady-state, oral
dose: 16 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
42.3 ng/mL
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
65.5 ng/mL
8 mg 1 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
162 ng × h/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
268 ng × h/mL
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.9 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
15 h
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
11.9 h
1 mg 1 times / day steady-state, oral
dose: 1 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
11.6 h
16 mg 1 times / day steady-state, oral
dose: 16 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12.8 h
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8.3 h
8 mg 1 times / day steady-state, oral
dose: 8 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DOXAZOSIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources:
healthy, 19 years
n = 1
Health Status: healthy
Age Group: 19 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Sinus tachycardia...
AEs leading to
discontinuation/dose reduction:
Sinus tachycardia (1 patient)
Sources:
16 mg single, oral (max)
Highest studied dose
Dose: 16 mg
Route: oral
Route: single
Dose: 16 mg
Sources:
unhealthy, adult
n = 665
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: unknown
Population Size: 665
Sources:
DLT: Postural edema...
Dose limiting toxicities:
Postural edema (2.7%)
Sources:
4 mg 1 times / day steady, oral
Recommended
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
healthy, adult
n = 35
Health Status: healthy
Age Group: adult
Sex: unknown
Population Size: 35
Sources:
Disc. AE: Orthostatic dizziness...
AEs leading to
discontinuation/dose reduction:
Orthostatic dizziness (1 patient)
Sources:
16 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy, mean 59 years
n = 97
Health Status: unhealthy
Condition: Hypertension
Age Group: mean 59 years
Sex: M+F
Population Size: 97
Sources:
Disc. AE: Fatigue, Urinary incontinence...
Other AEs: Rhinitis...
AEs leading to
discontinuation/dose reduction:
Fatigue (3 patients)
Urinary incontinence (2 patients)
Other AEs:
Rhinitis (1 patient)
Sources:
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: cocaine dependence
Population Size: 22
Sources:
Other AEs: Nausea, Constipation...
Other AEs:
Nausea (below serious, 2 patients)
Constipation (below serious, 1 patient)
Allergy (below serious, 1 patient)
Dizziness (below serious, 1 patient)
Numbness (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Sinus tachycardia 1 patient
Disc. AE
60 mg single, oral
Overdose
Dose: 60 mg
Route: oral
Route: single
Dose: 60 mg
Sources:
healthy, 19 years
n = 1
Health Status: healthy
Age Group: 19 years
Sex: F
Population Size: 1
Sources:
Postural edema 2.7%
DLT
16 mg single, oral (max)
Highest studied dose
Dose: 16 mg
Route: oral
Route: single
Dose: 16 mg
Sources:
unhealthy, adult
n = 665
Health Status: unhealthy
Condition: Hypertension
Age Group: adult
Sex: unknown
Population Size: 665
Sources:
Orthostatic dizziness 1 patient
Disc. AE
4 mg 1 times / day steady, oral
Recommended
Dose: 4 mg, 1 times / day
Route: oral
Route: steady
Dose: 4 mg, 1 times / day
Sources:
healthy, adult
n = 35
Health Status: healthy
Age Group: adult
Sex: unknown
Population Size: 35
Sources:
Rhinitis 1 patient
16 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy, mean 59 years
n = 97
Health Status: unhealthy
Condition: Hypertension
Age Group: mean 59 years
Sex: M+F
Population Size: 97
Sources:
Urinary incontinence 2 patients
Disc. AE
16 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy, mean 59 years
n = 97
Health Status: unhealthy
Condition: Hypertension
Age Group: mean 59 years
Sex: M+F
Population Size: 97
Sources:
Fatigue 3 patients
Disc. AE
16 mg 1 times / day steady, oral (max)
Highest studied dose
Dose: 16 mg, 1 times / day
Route: oral
Route: steady
Dose: 16 mg, 1 times / day
Sources:
unhealthy, mean 59 years
n = 97
Health Status: unhealthy
Condition: Hypertension
Age Group: mean 59 years
Sex: M+F
Population Size: 97
Sources:
Allergy below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: cocaine dependence
Population Size: 22
Sources:
Constipation below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: cocaine dependence
Population Size: 22
Sources:
Dizziness below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: cocaine dependence
Population Size: 22
Sources:
Numbness below serious, 1 patient
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: cocaine dependence
Population Size: 22
Sources:
Nausea below serious, 2 patients
8 mg 1 times / day steady, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 22
Health Status: unhealthy
Condition: cocaine dependence
Population Size: 22
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer








Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions.
2001
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.
2001
Is postural hypotension a real problem with antihypertensive medication?
2001
Lower urinary tract symptoms suggestive of benign prostatic obstruction--Triumph: the role of general practice databases.
2001
Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus.
2001
Reduced heat shock proteins: a mechanism to explain higher cardiovascular events associated with doxazosin.
2001 Apr
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
2001 Apr
Recent clinical trial highlights in hypertension.
2001 Apr
Lessons learned from prematurely terminated clinical trials.
2001 Aug
Apoptotic activity of doxazosin on prostate stroma in vitro is mediated through an autocrine expression of TGF-beta1.
2001 Aug 1
Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes.
2001 Dec
Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension.
2001 Dec 18
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
2001 Feb
Low-dose ACE with alpha- or beta-adrenergic receptor inhibitors have beneficial SHR cardiovascular effects.
2001 Jan
[Bilateral pheochromocytoma: laparoscopic surgery in 2 cases].
2001 Jan
A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster alpha1B-adrenoceptors.
2001 Jan
Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure.
2001 Jul
Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects.
2001 Jul
Role of alpha1-blockade in congenital long QT syndrome: investigation by exercise stress test.
2001 Jul
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
2001 Jul 1
Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy.
2001 Jul-Aug
[Long-term therapy of benign prostatic hyperplasia. Our experience].
2001 Mar
The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and alpha1-blockers.
2001 Mar
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
2001 May
Effect of antihypertensive therapy on renal artery structure in type 2 diabetic rats with hypertension.
2001 May
Doxazosin inhibits monocyte chemotactic protein 1-directed migration of human monocytes.
2001 May
[Alpha-blockers in therapy of arterial hypertension. No longer the drug of first choice].
2001 May 31
Effects of antihypertensive agents on blood pressure during exercise.
2001 Nov
Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial.
2001 Nov
Doxazosin and congestive heart failure.
2001 Nov 1
A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease.
2001 Oct
Heart lines. Cardura update.
2001 Sep
Effect of doxazosin on rat urinary bladder function after partial outlet obstruction.
2002
Influence of the alpha-1-adrenergic receptor blocker doxazosin on exercise-induced hyperkalemia in hemodialysis patients.
2002
Acute effects of serotonin on rat bladder contractility.
2002
Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma.
2002 Aug
Two-drug therapy is best for symptomatic prostate enlargement: combination should change clinical practice.
2002 Aug
Medical therapy for benign prostatic hyperplasia progression.
2002 Aug
Differential actions of naftopidil, doxazosin and nifedipine on platelet thromboxane generation and platelet-derived growth factor efflux in vitro.
2002 Aug-Sep
The use of alpha-adrenoceptor antagonists in lower urinary tract disease.
2002 Feb
Stability-indicating methods for the determination of doxazosin mezylate and celecoxib.
2002 Feb 1
Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation.
2002 Jan
Stroke associated with alpha blocker therapy for benign prostatic hypertrophy.
2002 Jan
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
2002 Jan 15
Psychological characteristics and responses to antihypertensive drug therapy.
2002 Jan-Feb
Treatment of hypertension in the elderly.
2002 Jan-Feb
alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia.
2002 Jul
Successful blood pressure control in the African American Study of Kidney Disease and Hypertension.
2002 Jul 22
Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
2002 May-Jun
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial.
2002 Sep 3
Patents

Patents

Sample Use Guides

Usual Adult Dose for Hypertension Initial dose: 1 mg orally once a day. Maintenance dose: 1 to 16 mg orally once a day. Usual Adult Dose for Benign Prostatic Hyperplasia Initial dose: Immediate-release: 1 mg orally once a day. Extended-release: 4 mg orally once a day with breakfast Maintenance dose: Immediate-release: 1 to 8 mg orally once a day. Extended-release: 4 to 8 mg orally once a day with breakfast. Depending on the patient's symptomatic response and tolerability, the dose may be increased to 8 mg (the maximum recommended dose). The recommended titration interval is 3 to 4 weeks.
Route of Administration: Oral
In Vitro Use Guide
Ring segments of splanchnic, peripheral, coronary, pulmonary and uterine conduit arteries obtained during surgery were studied in tissue baths. Resistance arteries dissected from various sites were studied in a myograph. Both conduit and resistance vessels contracted in response to the alpha 1-agonist phenylephrine (10(-7) to 10(-4) mol/l), an effect that was antagonized by the alpha 1-antagonist doxazosin (10(-8) to 10(-6) mol/l).
Name Type Language
DOXAZOSIN
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
DOXAZOSIN [MI]
Common Name English
C02CA04
Code English
1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-(1,4-BENZODIOXAN-2-YLCARBONYL)PIPERAZINE
Systematic Name English
(+/-)-DOXAZOSIN
Common Name English
DOXAZOSIN [WHO-DD]
Common Name English
(4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)METHANONE
Systematic Name English
DOXAZOSIN [INN]
Common Name English
PIPERAZINE, 1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-((2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)CARBONYL)-
Systematic Name English
DOXAZOSIN [VANDF]
Common Name English
METHANONE, (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)-
Systematic Name English
UK-33274
Code English
CARDURA XL
Brand Name English
Classification Tree Code System Code
NDF-RT N0000175553
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
NDF-RT N0000000099
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
NCI_THESAURUS C29713
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
LIVERTOX 325
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
WHO-VATC QC02CA04
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
WHO-ATC C02CA04
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
NCI_THESAURUS C29707
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
Code System Code Type Description
WIKIPEDIA
DOXAZOSIN
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
RXCUI
49276
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY RxNorm
CAS
74191-85-8
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
PUBCHEM
3157
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
LACTMED
Doxazosin
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
INN
5143
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
MERCK INDEX
M4752
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL707
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
IUPHAR
7170
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
DRUG CENTRAL
954
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
NCI_THESAURUS
C61737
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
EPA CompTox
74191-85-8
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
MESH
D017292
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
FDA UNII
NW1291F1W8
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
CAS
137888-77-8
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
SUPERSEDED
EVMPD
SUB06384MIG
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY
DRUG BANK
DB00590
Created by admin on Sat Jun 26 03:48:41 UTC 2021 , Edited by admin on Sat Jun 26 03:48:41 UTC 2021
PRIMARY